Scientific inquiry is inherently collaborative. Numerous consortiums and partnerships exist across various research disciplines, transcending geographical and linguistic boundaries. While some laboratories might secure additional financing from alternative sources such as the European Union, the likelihood of compensating for a sustained reduction in NIH funding through international support seems remote. Moreover, major pharmaceutical companies, despite their substantial financial resources, are not expected to step in, according to insights from sources consulted by WIRED.
“This responsibility can’t be transferred to pharmaceutical companies or biotech firms, as they typically lack interest in research at the preliminary stages we’re discussing,” explains a genetics professor who requested anonymity due to concerns about repercussions. “There exists a significant number of university-based researchers working tirelessly to uncover fundamental knowledge that eventually allows drug companies to invest $100 million.”
The substantial funding awarded to top-tier laboratories facilitates the employment of graduate students, lab technicians, and analysts. If a lead investigator fails to secure a grant through the process outlined by Keusch, the entire lab may face closure, resulting in job losses for these integral team members.
One potential consequence of losing NIH funding, even temporarily, could be a significant domestic brain drain. “Many of those individuals will seek alternative opportunities,” the genetics professor warns. “These positions are like any others—we cannot go without paying people for a month. Imagine if the food service sector or grocery stores didn’t pay their employees for an entire month; their workforce would leave, and the pharmaceutical industry can only employ so many.”
Repeatedly, WIRED was informed by scientists, hesitant to go on record for fear of jeopardizing their teams and jobs, that the repercussions will soon reach the general public. The reduction in research funding would likely lead to the closure of hospitals and universities, and progress in medical advancements may stall as well.
The conditions researched with NIH support extend beyond rare diseases impacting merely 1 or 2 percent of the population. They encompass critical health issues like cancer, diabetes, and Alzheimer’s—ailments that affect your loved ones, friends, and countless individuals who may one day face health challenges. The advancements in medical knowledge that empower doctors to treat heart attacks, manage diabetes, lower cholesterol, and mitigate stroke risks are largely due to this research infrastructure and dedicated scientists. “All of this valuable knowledge, generated by NIH-funded researchers, could face disruption if such a large obstacle is introduced,” remarks the genetics professor.
While there is some optimism that the academic funding hiatus could conclude on February 1, marking the expected resumption of grant reviews and communications, those interviewed by WIRED largely doubt that operations will simply revert to the previous status quo.
